Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | DNA topoisomerase 1 | 0.0227 | 0.6922 | 0.5 |
Schistosoma mansoni | DNA topoisomerase type I | 0.0227 | 0.6922 | 1 |
Plasmodium falciparum | topoisomerase I | 0.0227 | 0.6922 | 0.5 |
Plasmodium vivax | topoisomerase I, putative | 0.0227 | 0.6922 | 0.5 |
Loa Loa (eye worm) | DNA topoisomerase I | 0.0227 | 0.6922 | 0.5 |
Trypanosoma cruzi | squalene monooxygenase, putative | 0.0302 | 1 | 1 |
Echinococcus multilocularis | DNA topoisomerase 1 | 0.0227 | 0.6922 | 0.5 |
Trypanosoma brucei | DNA topoisomerase IB, large subunit | 0.017 | 0.4599 | 0.4599 |
Brugia malayi | DNA topoisomerase I | 0.0227 | 0.6922 | 0.5 |
Leishmania major | DNA topoisomerase IB, large subunit | 0.017 | 0.4599 | 0.4599 |
Trypanosoma cruzi | DNA topoisomerase IB, large subunit, putative | 0.017 | 0.4599 | 0.4599 |
Toxoplasma gondii | DNA topoisomerase I, putative | 0.0227 | 0.6922 | 0.5 |
Trypanosoma brucei | squalene monooxygenase, putative | 0.0302 | 1 | 1 |
Trypanosoma cruzi | squalene monooxygenase, putative | 0.0302 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.3663 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.